Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2008-05

AUTHORS

Preeti Gupta, M. Sinead O’Mahony

ABSTRACT

Asthma and chronic obstructive pulmonary disease (COPD) are common disorders that are associated with increasing morbidity and mortality in older people. Bronchodilators are used widely in patients with these conditions, but even when used in inhaled form can have systemic as well as local effects. Older people experience more adverse drug effects because of pharmacodynamic and pharmacokinetic changes and particularly drug-drug and drug-disease interactions.Cardiovascular disease is common in older people and β-adrenoceptor agonists (β-agonists) have inotropic and chronotropic effects that can increase arrhythmias and cardiomyopathy. They can also worsen or induce myocardial ischaemia and cause electrolyte disturbances that contribute to arrhythmias. Tremor is a well known distressing adverse effect of β-agonist administration. Long-term β-agonist use can be associated with tolerance, poor disease control, sudden life-threatening exacerbations and asthma-related deaths. Functional β2-adrenoceptors are present in osteoblasts, and chronic use of β-agonists has been implicated in osteoporosis.Inhaled anticholinergics are usually well tolerated but may cause dry mouth, which can be troublesome in older people. Pupillary dilatation, blurred vision and acute glaucoma can occur from escape of droplets from loosely fitting nebulizer masks. Although ECG changes have not been seen in randomized controlled trials of long-acting inhaled anticholinergics, supraventricular tachycardias have been observed in a 5-year randomized controlled trial of ipratropium bromide. Paradoxical bronchoconstriction can occur with inhaled anticholinergics as well as with β-agonists, but tolerance has not been reported with anticholinergics. Anticholinergic drugs also cause central effects, most notably impairment of cognitive function, and these effects have been noted with inhaled agents.Use of theophylline is limited by its adverse effects, which range from commonly occurring gastrointestinal symptoms to palpitations, arrhythmias and reports of myocardial infarction. Seizures have been reported, but are rare. Theophylline is metabolized primarily by the liver, and commonly interacts with other medications. Its concentration in plasma should be monitored closely, especially in older people.Although many clinical trials have been conducted on bronchodilators in obstructive airways disease, the results of these clinical trials need to be interpreted with caution as older people are often under-represented and subjects with co-morbidities actively excluded from these trials. More... »

PAGES

415-443

References to SciGraph publications

  • 1999-08. Age-related changes in muscarinic cholinoceptor function in guinea-pig and rat airways in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 2005-07-30. Effects of ageing on muscarinic receptor subtypes and function in rat urinary bladder in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 2006-05-09. Muscarinic receptor signaling in the pathophysiology of asthma and COPD in RESPIRATORY RESEARCH
  • 1989-01. The relationship between theophylline clearance and age in adult life in EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
  • 2006-10. Meta-analysis: Anticholinergics, but not β-agonists, reduce severe exacerbations and respiratory mortality in COPD in JOURNAL OF GENERAL INTERNAL MEDICINE
  • 2006-05-23. Negative impact of chronic obstructive pulmonary disease on the health-related quality of life of patients. Results of the EPIDEPOC study in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 1993-07. The Problems of Anticholinergic Adverse Effects in Older Patients in DRUGS & AGING
  • 2001-12. Asthma Medications and their Potential Adverse Effects in the Elderly in DRUG SAFETY
  • 2006-01-31. Limited β2-adrenoceptor haplotypes display different agonist mediated airway responses in asthmatics in RESPIRATORY RESEARCH
  • 2003-04. Use of M1–M5 Muscarinic Receptor Knockout Mice as Novel Tools to Delineate the Physiological Roles of the Muscarinic Cholinergic System in NEUROCHEMICAL RESEARCH
  • 1976-05. Plasma noradrenaline increases with age in NATURE
  • 1994-03. Physiological Changes Due to Age in DRUGS & AGING
  • 1977-06. Reduced β-adrenergic receptor concentrations in ageing man in NATURE
  • 1999-04. Functional assay of NF-κB translocation into nuclei by laser scanning cytometry: inhibitory effect by dexamethasone or theophylline in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 1999-12. Chronic Effects of Xanthines on Levels of Central Receptors in Mice in CELLULAR AND MOLECULAR NEUROBIOLOGY
  • 1997-11. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A in NATURE
  • 1990-01. Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution in NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY
  • 2004-08. A Benefit-Risk Assessment of Inhaled Long-Acting β2-Agonists in the Management of Obstructive Pulmonary Disease in DRUG SAFETY
  • 1990-12. Long-term efficacy of formoterol compared to salbutamol in LUNG
  • 1999-05. Impact of genetic polymorphisms of the β2‐adrenergic receptor on albuterol bronchodilator pharmacodynamics in CLINICAL PHARMACOLOGY & THERAPEUTICS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.2165/00002512-200825050-00005

    DOI

    http://dx.doi.org/10.2165/00002512-200825050-00005

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1001159573

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/18447405


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Cardiorespiratory Medicine and Haematology", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Adrenergic beta-Agonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Aged", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Asthma", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Bronchodilator Agents", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Cholinergic Antagonists", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Drug Prescriptions", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Humans", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Pulmonary Disease, Chronic Obstructive", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Theophylline", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK", 
              "id": "http://www.grid.ac/institutes/grid.416025.4", 
              "name": [
                "University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gupta", 
            "givenName": "Preeti", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK", 
              "id": "http://www.grid.ac/institutes/grid.416025.4", 
              "name": [
                "University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK"
              ], 
              "type": "Organization"
            }, 
            "familyName": "O\u2019Mahony", 
            "givenName": "M. Sinead", 
            "id": "sg:person.01154352424.25", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154352424.25"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/261333a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048784570", 
              "https://doi.org/10.1038/261333a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/267856a0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1042523748", 
              "https://doi.org/10.1038/267856a0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1016/s0009-9236(99)70071-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1013381298", 
              "https://doi.org/10.1016/s0009-9236(99)70071-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1022844517200", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028921874", 
              "https://doi.org/10.1023/a:1022844517200"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002512-199404030-00004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1016511455", 
              "https://doi.org/10.2165/00002512-199404030-00004"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002512-199303040-00004", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015621468", 
              "https://doi.org/10.2165/00002512-199303040-00004"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s002109900052", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036046641", 
              "https://doi.org/10.1007/s002109900052"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1111/j.1525-1497.2006.00507.x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030196607", 
              "https://doi.org/10.1111/j.1525-1497.2006.00507.x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002018-200427100-00001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048743769", 
              "https://doi.org/10.2165/00002018-200427100-00001"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1465-9921-7-73", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1005395823", 
              "https://doi.org/10.1186/1465-9921-7-73"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1023/a:1006901005925", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006782245", 
              "https://doi.org/10.1023/a:1006901005925"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf02718117", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012000274", 
              "https://doi.org/10.1007/bf02718117"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/pl00005349", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1008799663", 
              "https://doi.org/10.1007/pl00005349"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1477-7525-4-31", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035806986", 
              "https://doi.org/10.1186/1477-7525-4-31"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.2165/00002018-200124140-00005", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018020957", 
              "https://doi.org/10.2165/00002018-200124140-00005"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00195052", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1045072770", 
              "https://doi.org/10.1007/bf00195052"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/1465-9921-7-19", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1032946440", 
              "https://doi.org/10.1186/1465-9921-7-19"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/36362", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052687659", 
              "https://doi.org/10.1038/36362"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/bf00561019", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017264006", 
              "https://doi.org/10.1007/bf00561019"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s00210-005-1084-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028341993", 
              "https://doi.org/10.1007/s00210-005-1084-0"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2008-05", 
        "datePublishedReg": "2008-05-01", 
        "description": "Asthma and chronic obstructive pulmonary disease (COPD) are common disorders that are associated with increasing morbidity and mortality in older people. Bronchodilators are used widely in patients with these conditions, but even when used in inhaled form can have systemic as well as local effects. Older people experience more adverse drug effects because of pharmacodynamic and pharmacokinetic changes and particularly drug-drug and drug-disease interactions.Cardiovascular disease is common in older people and \u03b2-adrenoceptor agonists (\u03b2-agonists) have inotropic and chronotropic effects that can increase arrhythmias and cardiomyopathy. They can also worsen or induce myocardial ischaemia and cause electrolyte disturbances that contribute to arrhythmias. Tremor is a well known distressing adverse effect of \u03b2-agonist administration. Long-term \u03b2-agonist use can be associated with tolerance, poor disease control, sudden life-threatening exacerbations and asthma-related deaths. Functional \u03b22-adrenoceptors are present in osteoblasts, and chronic use of \u03b2-agonists has been implicated in osteoporosis.Inhaled anticholinergics are usually well tolerated but may cause dry mouth, which can be troublesome in older people. Pupillary dilatation, blurred vision and acute glaucoma can occur from escape of droplets from loosely fitting nebulizer masks. Although ECG changes have not been seen in randomized controlled trials of long-acting inhaled anticholinergics, supraventricular tachycardias have been observed in a 5-year randomized controlled trial of ipratropium bromide. Paradoxical bronchoconstriction can occur with inhaled anticholinergics as well as with \u03b2-agonists, but tolerance has not been reported with anticholinergics. Anticholinergic drugs also cause central effects, most notably impairment of cognitive function, and these effects have been noted with inhaled agents.Use of theophylline is limited by its adverse effects, which range from commonly occurring gastrointestinal symptoms to palpitations, arrhythmias and reports of myocardial infarction. Seizures have been reported, but are rare. Theophylline is metabolized primarily by the liver, and commonly interacts with other medications. Its concentration in plasma should be monitored closely, especially in older people.Although many clinical trials have been conducted on bronchodilators in obstructive airways disease, the results of these clinical trials need to be interpreted with caution as older people are often under-represented and subjects with co-morbidities actively excluded from these trials.", 
        "genre": "article", 
        "id": "sg:pub.10.2165/00002512-200825050-00005", 
        "isAccessibleForFree": false, 
        "isPartOf": [
          {
            "id": "sg:journal.1100990", 
            "issn": [
              "1170-229X", 
              "1179-1969"
            ], 
            "name": "Drugs & Aging", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "5", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "25"
          }
        ], 
        "keywords": [
          "chronic obstructive pulmonary disease", 
          "older people", 
          "clinical trials", 
          "adverse effects", 
          "life-threatening exacerbations", 
          "\u03b2-agonists", 
          "asthma-related deaths", 
          "obstructive pulmonary disease", 
          "\u03b2-agonist use", 
          "obstructive airways disease", 
          "adverse drug effects", 
          "use of theophylline", 
          "\u03b2-adrenoceptor agonists", 
          "poor disease control", 
          "drug-disease interactions", 
          "\u03b2-agonist administration", 
          "potential adverse effects", 
          "paradoxical bronchoconstriction", 
          "dry mouth", 
          "acute glaucoma", 
          "gastrointestinal symptoms", 
          "airway obstruction", 
          "electrolyte disturbances", 
          "airway disease", 
          "pulmonary disease", 
          "pharmacokinetic changes", 
          "ipratropium bromide", 
          "chronotropic effect", 
          "myocardial ischaemia", 
          "ECG changes", 
          "anticholinergic drugs", 
          "central effects", 
          "chronic use", 
          "pupillary dilatation", 
          "supraventricular tachycardia", 
          "myocardial infarction", 
          "common disorder", 
          "cardiovascular disease", 
          "drug effects", 
          "anticholinergics", 
          "bronchodilators", 
          "disease control", 
          "cognitive function", 
          "arrhythmias", 
          "trials", 
          "disease", 
          "theophylline", 
          "bronchoconstriction", 
          "palpitations", 
          "asthma", 
          "morbidity", 
          "inotropic", 
          "ischaemia", 
          "exacerbation", 
          "medications", 
          "tachycardia", 
          "infarction", 
          "patients", 
          "cardiomyopathy", 
          "osteoporosis", 
          "glaucoma", 
          "seizures", 
          "dilatation", 
          "agonists", 
          "obstruction", 
          "local effects", 
          "symptoms", 
          "mortality", 
          "liver", 
          "administration", 
          "impairment", 
          "tremor", 
          "disorders", 
          "drugs", 
          "death", 
          "effect", 
          "people", 
          "treatment", 
          "subjects", 
          "report", 
          "osteoblasts", 
          "use", 
          "tolerance", 
          "caution", 
          "changes", 
          "agents", 
          "mouth", 
          "control", 
          "plasma", 
          "disturbances", 
          "escape", 
          "concentration", 
          "acting", 
          "function", 
          "vision", 
          "results", 
          "mask", 
          "form", 
          "conditions", 
          "interaction", 
          "bromide", 
          "droplets"
        ], 
        "name": "Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People", 
        "pagination": "415-443", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1001159573"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.2165/00002512-200825050-00005"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "18447405"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.2165/00002512-200825050-00005", 
          "https://app.dimensions.ai/details/publication/pub.1001159573"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-08-04T16:58", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220804/entities/gbq_results/article/article_470.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.2165/00002512-200825050-00005"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.2165/00002512-200825050-00005'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.2165/00002512-200825050-00005'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.2165/00002512-200825050-00005'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.2165/00002512-200825050-00005'


     

    This table displays all metadata directly associated to this object as RDF triples.

    289 TRIPLES      21 PREDICATES      158 URIs      129 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.2165/00002512-200825050-00005 schema:about N51e3eac893ae4b4bbdcdfa7422be9101
    2 N677d7e50375145d1ae82a835650a8981
    3 N6bf5bdd3e65e480b8da52d487c1610d0
    4 N7c447b7b207e4dddafd26fc8cdda1e06
    5 N897565ee29cd4cf09259ac709ef28cd7
    6 Nb2576c05a39046b38c2191e08919de88
    7 Ndadc6da5d4fc4933aa1990b2e6cbdf11
    8 Nf77aaddeefb642ae902e5e9cfce398c8
    9 Nf8ede4dc643c4283bc74300db26c22b1
    10 anzsrc-for:11
    11 anzsrc-for:1102
    12 anzsrc-for:1103
    13 schema:author Ndf60937dbfe0492e8f1404c371dafb0e
    14 schema:citation sg:pub.10.1007/bf00195052
    15 sg:pub.10.1007/bf00561019
    16 sg:pub.10.1007/bf02718117
    17 sg:pub.10.1007/pl00005349
    18 sg:pub.10.1007/s00210-005-1084-0
    19 sg:pub.10.1007/s002109900052
    20 sg:pub.10.1016/s0009-9236(99)70071-8
    21 sg:pub.10.1023/a:1006901005925
    22 sg:pub.10.1023/a:1022844517200
    23 sg:pub.10.1038/261333a0
    24 sg:pub.10.1038/267856a0
    25 sg:pub.10.1038/36362
    26 sg:pub.10.1111/j.1525-1497.2006.00507.x
    27 sg:pub.10.1186/1465-9921-7-19
    28 sg:pub.10.1186/1465-9921-7-73
    29 sg:pub.10.1186/1477-7525-4-31
    30 sg:pub.10.2165/00002018-200124140-00005
    31 sg:pub.10.2165/00002018-200427100-00001
    32 sg:pub.10.2165/00002512-199303040-00004
    33 sg:pub.10.2165/00002512-199404030-00004
    34 schema:datePublished 2008-05
    35 schema:datePublishedReg 2008-05-01
    36 schema:description Asthma and chronic obstructive pulmonary disease (COPD) are common disorders that are associated with increasing morbidity and mortality in older people. Bronchodilators are used widely in patients with these conditions, but even when used in inhaled form can have systemic as well as local effects. Older people experience more adverse drug effects because of pharmacodynamic and pharmacokinetic changes and particularly drug-drug and drug-disease interactions.Cardiovascular disease is common in older people and β-adrenoceptor agonists (β-agonists) have inotropic and chronotropic effects that can increase arrhythmias and cardiomyopathy. They can also worsen or induce myocardial ischaemia and cause electrolyte disturbances that contribute to arrhythmias. Tremor is a well known distressing adverse effect of β-agonist administration. Long-term β-agonist use can be associated with tolerance, poor disease control, sudden life-threatening exacerbations and asthma-related deaths. Functional β2-adrenoceptors are present in osteoblasts, and chronic use of β-agonists has been implicated in osteoporosis.Inhaled anticholinergics are usually well tolerated but may cause dry mouth, which can be troublesome in older people. Pupillary dilatation, blurred vision and acute glaucoma can occur from escape of droplets from loosely fitting nebulizer masks. Although ECG changes have not been seen in randomized controlled trials of long-acting inhaled anticholinergics, supraventricular tachycardias have been observed in a 5-year randomized controlled trial of ipratropium bromide. Paradoxical bronchoconstriction can occur with inhaled anticholinergics as well as with β-agonists, but tolerance has not been reported with anticholinergics. Anticholinergic drugs also cause central effects, most notably impairment of cognitive function, and these effects have been noted with inhaled agents.Use of theophylline is limited by its adverse effects, which range from commonly occurring gastrointestinal symptoms to palpitations, arrhythmias and reports of myocardial infarction. Seizures have been reported, but are rare. Theophylline is metabolized primarily by the liver, and commonly interacts with other medications. Its concentration in plasma should be monitored closely, especially in older people.Although many clinical trials have been conducted on bronchodilators in obstructive airways disease, the results of these clinical trials need to be interpreted with caution as older people are often under-represented and subjects with co-morbidities actively excluded from these trials.
    37 schema:genre article
    38 schema:isAccessibleForFree false
    39 schema:isPartOf N50fe8471b4a74c1b9a016401d1c04067
    40 N85d1ce8d76f94c83bba7cc03c45c8b75
    41 sg:journal.1100990
    42 schema:keywords ECG changes
    43 acting
    44 acute glaucoma
    45 administration
    46 adverse drug effects
    47 adverse effects
    48 agents
    49 agonists
    50 airway disease
    51 airway obstruction
    52 anticholinergic drugs
    53 anticholinergics
    54 arrhythmias
    55 asthma
    56 asthma-related deaths
    57 bromide
    58 bronchoconstriction
    59 bronchodilators
    60 cardiomyopathy
    61 cardiovascular disease
    62 caution
    63 central effects
    64 changes
    65 chronic obstructive pulmonary disease
    66 chronic use
    67 chronotropic effect
    68 clinical trials
    69 cognitive function
    70 common disorder
    71 concentration
    72 conditions
    73 control
    74 death
    75 dilatation
    76 disease
    77 disease control
    78 disorders
    79 disturbances
    80 droplets
    81 drug effects
    82 drug-disease interactions
    83 drugs
    84 dry mouth
    85 effect
    86 electrolyte disturbances
    87 escape
    88 exacerbation
    89 form
    90 function
    91 gastrointestinal symptoms
    92 glaucoma
    93 impairment
    94 infarction
    95 inotropic
    96 interaction
    97 ipratropium bromide
    98 ischaemia
    99 life-threatening exacerbations
    100 liver
    101 local effects
    102 mask
    103 medications
    104 morbidity
    105 mortality
    106 mouth
    107 myocardial infarction
    108 myocardial ischaemia
    109 obstruction
    110 obstructive airways disease
    111 obstructive pulmonary disease
    112 older people
    113 osteoblasts
    114 osteoporosis
    115 palpitations
    116 paradoxical bronchoconstriction
    117 patients
    118 people
    119 pharmacokinetic changes
    120 plasma
    121 poor disease control
    122 potential adverse effects
    123 pulmonary disease
    124 pupillary dilatation
    125 report
    126 results
    127 seizures
    128 subjects
    129 supraventricular tachycardia
    130 symptoms
    131 tachycardia
    132 theophylline
    133 tolerance
    134 treatment
    135 tremor
    136 trials
    137 use
    138 use of theophylline
    139 vision
    140 β-adrenoceptor agonists
    141 β-agonist administration
    142 β-agonist use
    143 β-agonists
    144 schema:name Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People
    145 schema:pagination 415-443
    146 schema:productId N68eb70d22f144862843cb017d250c4f2
    147 N85f333cad4604cc1b49220325501f1f1
    148 Nf28a8058e0004ffcae69d9e8b1c489bc
    149 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001159573
    150 https://doi.org/10.2165/00002512-200825050-00005
    151 schema:sdDatePublished 2022-08-04T16:58
    152 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    153 schema:sdPublisher N2aefea550036492bab91c73a760382d6
    154 schema:url https://doi.org/10.2165/00002512-200825050-00005
    155 sgo:license sg:explorer/license/
    156 sgo:sdDataset articles
    157 rdf:type schema:ScholarlyArticle
    158 N2aefea550036492bab91c73a760382d6 schema:name Springer Nature - SN SciGraph project
    159 rdf:type schema:Organization
    160 N50fe8471b4a74c1b9a016401d1c04067 schema:volumeNumber 25
    161 rdf:type schema:PublicationVolume
    162 N51e3eac893ae4b4bbdcdfa7422be9101 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Bronchodilator Agents
    164 rdf:type schema:DefinedTerm
    165 N677d7e50375145d1ae82a835650a8981 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Adrenergic beta-Agonists
    167 rdf:type schema:DefinedTerm
    168 N68eb70d22f144862843cb017d250c4f2 schema:name dimensions_id
    169 schema:value pub.1001159573
    170 rdf:type schema:PropertyValue
    171 N6bf5bdd3e65e480b8da52d487c1610d0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    172 schema:name Theophylline
    173 rdf:type schema:DefinedTerm
    174 N7c447b7b207e4dddafd26fc8cdda1e06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    175 schema:name Asthma
    176 rdf:type schema:DefinedTerm
    177 N85d1ce8d76f94c83bba7cc03c45c8b75 schema:issueNumber 5
    178 rdf:type schema:PublicationIssue
    179 N85f333cad4604cc1b49220325501f1f1 schema:name pubmed_id
    180 schema:value 18447405
    181 rdf:type schema:PropertyValue
    182 N897565ee29cd4cf09259ac709ef28cd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Humans
    184 rdf:type schema:DefinedTerm
    185 N9472f4388c2649748751af3ef6d099b6 schema:affiliation grid-institutes:grid.416025.4
    186 schema:familyName Gupta
    187 schema:givenName Preeti
    188 rdf:type schema:Person
    189 Nb2576c05a39046b38c2191e08919de88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    190 schema:name Cholinergic Antagonists
    191 rdf:type schema:DefinedTerm
    192 Ndadc6da5d4fc4933aa1990b2e6cbdf11 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    193 schema:name Aged
    194 rdf:type schema:DefinedTerm
    195 Ndf60937dbfe0492e8f1404c371dafb0e rdf:first N9472f4388c2649748751af3ef6d099b6
    196 rdf:rest Ne432bd30121b4b50ab57f2e841ff4c9a
    197 Ne432bd30121b4b50ab57f2e841ff4c9a rdf:first sg:person.01154352424.25
    198 rdf:rest rdf:nil
    199 Nf28a8058e0004ffcae69d9e8b1c489bc schema:name doi
    200 schema:value 10.2165/00002512-200825050-00005
    201 rdf:type schema:PropertyValue
    202 Nf77aaddeefb642ae902e5e9cfce398c8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    203 schema:name Pulmonary Disease, Chronic Obstructive
    204 rdf:type schema:DefinedTerm
    205 Nf8ede4dc643c4283bc74300db26c22b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    206 schema:name Drug Prescriptions
    207 rdf:type schema:DefinedTerm
    208 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    209 schema:name Medical and Health Sciences
    210 rdf:type schema:DefinedTerm
    211 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
    212 schema:name Cardiorespiratory Medicine and Haematology
    213 rdf:type schema:DefinedTerm
    214 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    215 schema:name Clinical Sciences
    216 rdf:type schema:DefinedTerm
    217 sg:journal.1100990 schema:issn 1170-229X
    218 1179-1969
    219 schema:name Drugs & Aging
    220 schema:publisher Springer Nature
    221 rdf:type schema:Periodical
    222 sg:person.01154352424.25 schema:affiliation grid-institutes:grid.416025.4
    223 schema:familyName O’Mahony
    224 schema:givenName M. Sinead
    225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01154352424.25
    226 rdf:type schema:Person
    227 sg:pub.10.1007/bf00195052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045072770
    228 https://doi.org/10.1007/bf00195052
    229 rdf:type schema:CreativeWork
    230 sg:pub.10.1007/bf00561019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017264006
    231 https://doi.org/10.1007/bf00561019
    232 rdf:type schema:CreativeWork
    233 sg:pub.10.1007/bf02718117 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012000274
    234 https://doi.org/10.1007/bf02718117
    235 rdf:type schema:CreativeWork
    236 sg:pub.10.1007/pl00005349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008799663
    237 https://doi.org/10.1007/pl00005349
    238 rdf:type schema:CreativeWork
    239 sg:pub.10.1007/s00210-005-1084-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028341993
    240 https://doi.org/10.1007/s00210-005-1084-0
    241 rdf:type schema:CreativeWork
    242 sg:pub.10.1007/s002109900052 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036046641
    243 https://doi.org/10.1007/s002109900052
    244 rdf:type schema:CreativeWork
    245 sg:pub.10.1016/s0009-9236(99)70071-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013381298
    246 https://doi.org/10.1016/s0009-9236(99)70071-8
    247 rdf:type schema:CreativeWork
    248 sg:pub.10.1023/a:1006901005925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006782245
    249 https://doi.org/10.1023/a:1006901005925
    250 rdf:type schema:CreativeWork
    251 sg:pub.10.1023/a:1022844517200 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028921874
    252 https://doi.org/10.1023/a:1022844517200
    253 rdf:type schema:CreativeWork
    254 sg:pub.10.1038/261333a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048784570
    255 https://doi.org/10.1038/261333a0
    256 rdf:type schema:CreativeWork
    257 sg:pub.10.1038/267856a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042523748
    258 https://doi.org/10.1038/267856a0
    259 rdf:type schema:CreativeWork
    260 sg:pub.10.1038/36362 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052687659
    261 https://doi.org/10.1038/36362
    262 rdf:type schema:CreativeWork
    263 sg:pub.10.1111/j.1525-1497.2006.00507.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1030196607
    264 https://doi.org/10.1111/j.1525-1497.2006.00507.x
    265 rdf:type schema:CreativeWork
    266 sg:pub.10.1186/1465-9921-7-19 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032946440
    267 https://doi.org/10.1186/1465-9921-7-19
    268 rdf:type schema:CreativeWork
    269 sg:pub.10.1186/1465-9921-7-73 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005395823
    270 https://doi.org/10.1186/1465-9921-7-73
    271 rdf:type schema:CreativeWork
    272 sg:pub.10.1186/1477-7525-4-31 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035806986
    273 https://doi.org/10.1186/1477-7525-4-31
    274 rdf:type schema:CreativeWork
    275 sg:pub.10.2165/00002018-200124140-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018020957
    276 https://doi.org/10.2165/00002018-200124140-00005
    277 rdf:type schema:CreativeWork
    278 sg:pub.10.2165/00002018-200427100-00001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048743769
    279 https://doi.org/10.2165/00002018-200427100-00001
    280 rdf:type schema:CreativeWork
    281 sg:pub.10.2165/00002512-199303040-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015621468
    282 https://doi.org/10.2165/00002512-199303040-00004
    283 rdf:type schema:CreativeWork
    284 sg:pub.10.2165/00002512-199404030-00004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016511455
    285 https://doi.org/10.2165/00002512-199404030-00004
    286 rdf:type schema:CreativeWork
    287 grid-institutes:grid.416025.4 schema:alternateName University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK
    288 schema:name University Department of Geriatric Medicine, Academic Centre, Llandough Hospital, Cardiff, UK
    289 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...